#1 Clinical Trials Search in Europe

Doravirine

Doravirine is a novel antiretroviral medication being studied in clinical trials for the treatment of HIV infection. These trials aim to evaluate doravirine’s safety, efficacy, and pharmacokinetics in various patient populations, including those with renal or hepatic impairment, pregnant women, and elderly patients. The studies also examine doravirine’s ability to suppress viral replication in genital fluids and its potential use in patients with multiple drug resistance.

Table of Contents

What is Doravirine?

Doravirine, also known by its brand names Pifeltro and MK-1439, is a medication used to treat Human Immunodeficiency Virus (HIV) infection[1]. It belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs)[2]. Doravirine is often used in combination with other antiretroviral medications to effectively manage HIV-1 infection[3].

How Doravirine Works

Doravirine works by inhibiting an enzyme called reverse transcriptase, which is essential for HIV to replicate itself. By blocking this enzyme, doravirine helps prevent the virus from multiplying and spreading in the body[2]. This mechanism of action helps to maintain viral suppression in HIV-infected patients, which is crucial for preventing disease progression, optimizing immune restoration, and reducing viral transmission[1].

Conditions Treated with Doravirine

Doravirine is primarily used to treat HIV-1 infection in adults[1]. It can be used in various scenarios:

  • As part of initial therapy for newly diagnosed HIV patients
  • As a switch option for patients who are already on antiretroviral therapy but need to change their regimen due to side effects or other reasons[4]
  • In patients with multiple drug resistance, including resistance to other NNRTIs[4]

Dosage and Administration

Doravirine is typically administered as a 100 mg tablet taken once daily, with or without food[3]. It is often used in combination with other antiretroviral drugs. For example, it may be combined with tenofovir alafenamide (TAF) and emtricitabine (FTC) in a single tablet regimen[3].

Efficacy and Safety

Clinical trials have shown that doravirine is effective in maintaining viral suppression in HIV-1 infected patients. It has demonstrated non-inferiority (meaning it works at least as well as) when compared to other antiretroviral regimens containing efavirenz or boosted darunavir[5]. Doravirine has also shown a favorable safety profile with fewer neuropsychiatric side effects compared to efavirenz and a better lipid profile compared to boosted darunavir[5].

Doravirine in Special Populations

Research is ongoing to understand how doravirine works in special populations:

  • Patients with renal impairment: Studies have shown that no dosage adjustment is required for patients with mild, moderate, or severe renal impairment[6]. However, more research is needed for patients with end-stage renal disease on dialysis[7].
  • Patients with hepatic impairment: Research has been conducted to understand how liver problems affect the way the body processes doravirine[2].
  • Elderly patients: Studies are being conducted to evaluate the effectiveness and safety of doravirine in HIV-infected patients over 50 years old[5].
  • Pregnant women: Research is ongoing to determine the appropriate dosing of doravirine during pregnancy[8].

Potential Side Effects

While doravirine is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include nausea, dizziness, and headache. However, doravirine has shown a superior neuropsychiatric profile compared to some other HIV medications[5]. It’s important to discuss any side effects with your healthcare provider.

Drug Interactions

Doravirine has a low potential for drug-drug interactions, which is an advantage, especially for patients taking multiple medications[5]. However, it’s always important to inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements.

Ongoing Research

Several studies are currently underway to further understand the benefits and potential uses of doravirine:

  • Its use in post-exposure prophylaxis (PEP) for HIV prevention[9]
  • Its effectiveness when used in dual therapy with other antiretroviral drugs[1]
  • Its concentration and antiviral activity in genital fluids, which could have implications for HIV transmission prevention[3]

As research continues, our understanding of doravirine and its potential benefits in HIV treatment will continue to grow.

Aspect Details
Drug Name Doravirine (MK-1439, PIFELTRO)
Drug Class Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Administration 100 mg tablet, taken orally once daily
Primary Outcomes Pharmacokinetics, viral suppression, safety profile
Special Populations Studied Renal impairment, hepatic insufficiency, pregnant women, elderly patients
Combination Therapies Studied with tenofovir alafenamide/emtricitabine (TAF/FTC)
Potential Applications HIV treatment, post-exposure prophylaxis, multiple drug-resistant HIV
Key Advantages Low propensity for resistance, excellent tolerability, minimal drug interactions

FAQ

  • What is doravirine? Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. It works by blocking the action of reverse transcriptase, an enzyme that HIV needs to multiply.
  • How is doravirine administered? Doravirine is typically administered as a 100 mg tablet taken orally once daily, with or without food. It may be given alone or in combination with other antiretroviral medications.
  • What patient populations are being studied in doravirine clinical trials? Clinical trials are evaluating doravirine in various populations, including patients with renal impairment, hepatic insufficiency, pregnant women, elderly patients, and those with multiple drug resistance.
  • What are the main outcomes being measured in these trials? The trials are primarily measuring doravirine's pharmacokinetics (how the drug moves through the body), its ability to suppress HIV viral load, and its safety profile in different patient groups.
  • Are there any special considerations for doravirine use in certain populations? Yes, the trials are investigating whether dosage adjustments may be necessary for patients with severe renal impairment or hepatic insufficiency. They are also studying doravirine's safety and efficacy in pregnant women and elderly patients.

Ongoing Clinical Trials on Doravirine

  • Study Comparing Doravirine/Lamivudine and Dolutegravir/Lamivudine for HIV Patients with Controlled Viral Load on Three-Drug Regimens

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Doravirine, Tenofovir Disoproxil, and Lamivudine in HIV Patients with M184V/I Mutation and Controlled Viral Load

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • A Study of Doravirine for Early Treatment of West Nile Virus Infection in Patients at Risk of Disease Worsening

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Doravirine and Raltegravir for Maintaining Viral Control in HIV Patients with Low Viral Load

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study on Switching to Doravirine and Islatravir for People with HIV-1 on Antiretroviral Therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Finland France Germany Italy Poland Spain

  • Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Viral load: The amount of HIV in a person's blood, typically measured as the number of copies of the virus per milliliter of blood.
  • Non-nucleoside reverse transcriptase inhibitor (NNRTI): A class of antiretroviral drugs that block the action of reverse transcriptase, an enzyme HIV needs to multiply.
  • Renal impairment: Reduced kidney function that can affect how drugs are processed and eliminated from the body.
  • Hepatic insufficiency: Reduced liver function that can impact drug metabolism and clearance.
  • Antiretroviral therapy (ART): The use of HIV medicines to treat HIV infection, typically involving a combination of different drugs.
  • Virological efficacy: The ability of a treatment to suppress HIV replication and reduce viral load to undetectable levels.
  • Post-exposure prophylaxis (PEP): The use of antiretroviral medications after potential exposure to HIV to prevent infection.
  • Genotypic resistance: The presence of genetic mutations in HIV that can make the virus less susceptible to certain antiretroviral drugs.
  • Steady state: The point at which the rate of drug intake equals the rate of drug elimination, resulting in a stable concentration of the drug in the body.

References

  1. https://clinicaltrials.eu/trial/study-on-doravirine-and-raltegravir-for-maintaining-viral-control-in-hiv-patients-with-low-viral-load/
  2. https://clinicaltrials.gov/study/NCT02089659
  3. https://clinicaltrials.gov/study/NCT04097925
  4. https://clinicaltrials.gov/study/NCT04334551
  5. https://clinicaltrials.gov/study/NCT05202613
  6. https://clinicaltrials.gov/study/NCT02641067
  7. https://clinicaltrials.gov/study/NCT04689737
  8. https://clinicaltrials.gov/study/NCT04900974
  9. https://clinicaltrials.gov/study/NCT05761509